Tus kws kho mob
P61-21 Evaluation and Management Reimbursement Changes
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2021
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 1431 - 1440 ntawm 4303
Tus kws kho mob
P55R1-21 Update: Early Intensive Developmental and Behavioral Intervention (EIDBI) Service Authorization and Claims Submission for Minnesota Health Care Programs
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2021
Tus kws kho mob
P60-21 Sequestration Reinstated January 1, 2022
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2021
Tus kws kho mob
P62-21 eviCore Healthcare Enhanced Utilization Management (UM) now being offered to Self-Insured Groups
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2021
Tus kws kho mob
P63-21 Member Protections from Conversion Therapy
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2021
Tus kws kho mob
P64-21 Update to Reimbursement Policy Durable Medical Equipment (DME) - 002 Oxygen Aiding Equipment
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2021
Tus kws kho mob
P65-21 Change in Claim Submission for Medicare Members for COVID-19 Vaccines and Monoclonal Antibody Treatment
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2021
Tus kws kho mob
P66-21 New Medical, Medical Drug and Behavioral Health Policy Management Updates—Effective January 3, 2022
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2021
Tus kws kho mob
P67-21 Medical Drug Policy Update – Infliximab Preferred Product Expansion to Include Remicade, Inflectra, and Renflexis
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2021
Tus kws kho mob
P68-21 eviCore Healthcare Specialty Utilization Management (UM) Program - Laboratory Management Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2021